LKFT
Income statement / Annual
Last year (2025), Lakefront Biotherapeutics NV's total revenue was $1.11 B,
and the percentage change from the previous year is not available.
In 2025, Lakefront Biotherapeutics NV's net income was $320.88 M.
See Lakefront Biotherapeutics NV,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
| Period Ended |
12/31/2025 |
| Operating Revenue |
$1.11 B |
| Cost of Revenue |
$29.74 M
|
| Gross Profit |
$1.08 B
|
| Gross Profit Ratio |
0.97
|
| Research and Development Expenses |
$459.42 M
|
| General & Administrative Expenses |
$110.57 M
|
| Selling & Marketing Expenses |
$1.39 M
|
| Selling, General & Administrative Expenses |
$111.96 M
|
| Other Expenses |
$9.74 M
|
| Operating Expenses |
$581.12 M
|
| Cost And Expenses |
$610.86 M
|
| Interest Income |
$46.34 M
|
| Interest Expense |
$2.22 M
|
| Depreciation & Amortization |
$55.88 M
|
| EBITDA |
$358.96 M |
| EBITDA Ratio |
0.32
|
| Operating Income Ratio |
0.45
|
| Total Other Income/Expenses Net |
-$200.52 M
|
| Income Before Tax |
$300.87 M
|
| Income Before Tax Ratio |
0.27
|
| Income Tax Expense |
-$18.62 M
|
| Net Income |
$320.88 M
|
| Net Income Ratio |
0.29
|
| EPS |
4.87 |
| EPS Diluted |
4.87 |
| Weighted Average Shares Out |
$65.90 M
|
| Weighted Average Shares Out Diluted |
$65.90 M
|
| Link |
|
